| Chi-hwa Yeh, MD | |
|
1511 W Mcdermott Dr Ste 240, Allen, TX 75013-4693 | |
| (469) 342-6303 | |
| (469) 342-6301 |
| Full Name | Chi-hwa Yeh |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 33 Years |
| Location | 1511 W Mcdermott Dr Ste 240, Allen, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912970146 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | J2426 (Texas) | Primary |
| Entity Name | Primamed Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164494068 PECOS PAC ID: 9234027897 Enrollment ID: O20040316000446 |
News Archive
Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).
FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.
There is little doubt that the Human Immunodeficiency Virus, or HIV, is devastating. More than 1.2 million people in the United States are living with HIV and more than 47,000 people are diagnosed annually. Now, University of Missouri researchers have made a discovery in how specialized proteins can inhibit the virus, opening the door for progress in the fight against HIV and for the production of advanced therapeutics to combat the disease.
The EU faces alarming increases in obesity and associated health problems such as cardiovascular disease, cancer and diabetes.
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
› Verified 2 days ago
| Entity Name | Allen Friends & Family Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164773842 PECOS PAC ID: 0042465056 Enrollment ID: O20130223000052 |
News Archive
Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).
FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.
There is little doubt that the Human Immunodeficiency Virus, or HIV, is devastating. More than 1.2 million people in the United States are living with HIV and more than 47,000 people are diagnosed annually. Now, University of Missouri researchers have made a discovery in how specialized proteins can inhibit the virus, opening the door for progress in the fight against HIV and for the production of advanced therapeutics to combat the disease.
The EU faces alarming increases in obesity and associated health problems such as cardiovascular disease, cancer and diabetes.
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chi-hwa Yeh, MD 1511 W Mcdermott Dr Ste 240, Allen, TX 75013-4693 Ph: (469) 342-6303 | Chi-hwa Yeh, MD 1511 W Mcdermott Dr Ste 240, Allen, TX 75013-4693 Ph: (469) 342-6303 |
News Archive
Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).
FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.
There is little doubt that the Human Immunodeficiency Virus, or HIV, is devastating. More than 1.2 million people in the United States are living with HIV and more than 47,000 people are diagnosed annually. Now, University of Missouri researchers have made a discovery in how specialized proteins can inhibit the virus, opening the door for progress in the fight against HIV and for the production of advanced therapeutics to combat the disease.
The EU faces alarming increases in obesity and associated health problems such as cardiovascular disease, cancer and diabetes.
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
› Verified 2 days ago
Dr. Astrid Gutsmann, DO, PH.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 411 E Mcdermott Dr, Allen, TX 75002 Phone: 972-227-3464 Fax: 972-359-9690 | |
Sovannarat Floyd, FNP-BC Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 906 W Mcdermott Dr Ste 124, Allen, TX 75013 Phone: 469-564-1026 | |
Dr. Sadaf Sadruddin Sabzali, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1650 E Stacy Rd Ste 160, Allen, TX 75002 Phone: 214-726-9098 Fax: 972-727-0842 | |
Dr. Nicholas Owon Kpar Atudonyang, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 977 Raintree Cir, Suite 210, Allen, TX 75013 Phone: 214-865-6648 Fax: 214-865-6646 | |
Wallace B Sarver, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1650 E Stacy Rd Ste 160, Allen, TX 75002 Phone: 214-726-9098 Fax: 972-727-0842 | |
Dr. Jeffrey L Burchard, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1105 Central Expy N, Ste 110, Allen, TX 75013 Phone: 972-727-9877 Fax: 972-727-5015 | |
Oyindamola Ojuolape Wemimo, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1218 W Mcdermott Dr, Allen, TX 75013 Phone: 972-390-9000 |